Mitigation and management of adverse events associated with amivantamab therapy
The Oncologist · 04.07.2025 · 30 (7)
DOI: 10.1093/oncolo/oyaf194 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 22.07.2025. Verfasst von Narjust Florez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Bispecific. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.
Themen: Patientensicherheit
Abstract (Originalsprache)
Amivantamab is a fully human bispecific epidermal growth factor receptor (EGFR)–directed and mesenchymal epithelial transition (MET) receptor–directed antibody. Intravenous amivantamab is approved and recommended by treatment guidelines as a first-line treatment (1L) in combination with lazertinib, as a second-line treatment (2L) in combination with chemotherapy in adults with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, and as 2L monotherapy or 1L in combination with chemotherapy in adults with advanced or metastatic NSCLC with exon 20 insertion-mutations. Compared with previous therapies, novel treatments such as amivantamab may be associated with distinct and unique adverse reactions that potentially require optimized prevention and management techniques. Commonly reported adverse reactions associated with amivantamab treatment regimens include cutaneous reactions associated with EGFR inhibition, such as rash, paronychia, and pruritus; those associated with MET inhibition, such as peripheral edema and hypoalbuminemia; and general effects, such as infusion-related reactions. Recommendations are summarized from published guidelines and the authors’ clinical experience for the prevention and management of adverse reactions associated with amivantamab. An understanding of the expected adverse events with amivantamab regimens, along with the range of prophylactic and management options available, may facilitate maintenance of ongoing treatment in patients deriving clinical benefit and improve patient quality of life on therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Brigham and Women's Hospital, Boston, MA, USA.
- NYU Langone Health, New York, NY, USA.
- Instituto Nacional de Cancerología, Mexico City, Mexico.
- Instituto D'or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil.
ORCID-Profile: Narjust Florez, Nicole R LeBoeuf, Julia Rotow, Jennifer A Marks, Joshua K Sabari, Oscar Arrieta, Clarissa Baldotto, Paul Cifuentes, Beth McLellan, Natasha B Leighl
Förderung
- Johnson & Johnson
Zitieren
APA
Florez, N., LeBoeuf, N. R., Rotow, J., Marks, J. A., Sabari, J. K., Arrieta, O., Baldotto, C., Gosain, R., Zawisza, D., McDonald, S., Dylgjeri, E., Cifuentes, P., McLellan, B., & Leighl, N. B. (2025). Mitigation and management of adverse events associated with amivantamab therapy. The Oncologist, 30(7). https://doi.org/10.1093/oncolo/oyaf194
Vancouver
Florez N, LeBoeuf NR, Rotow J, Marks JA, Sabari JK, Arrieta O, et al. Mitigation and management of adverse events associated with amivantamab therapy. The Oncologist. 2025;30(7). doi:10.1093/oncolo/oyaf194
BibTeX
@article{Florez2025,
author = {Florez, Narjust and LeBoeuf, Nicole R and Rotow, Julia and Marks, Jennifer A and Sabari, Joshua K and Arrieta, Oscar and Baldotto, Clarissa and Gosain, Rahul and Zawisza, Dianne and McDonald, Stephanie and Dylgjeri, Emanuela and Cifuentes, Paul and McLellan, Beth and Leighl, Natasha B},
title = {Mitigation and management of adverse events associated with amivantamab therapy},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {7},
doi = {10.1093/oncolo/oyaf194}
}
EUVIMED